In two studies in agitated patients with schizophrenia, ABILIFY® (aripiprazole) Injection and Haldol® (haloperidol) intramuscular, a common conventional antipsychotic frequently used for acutely ...

NEW YORK-- (BUSINESS WIRE)--Patients with schizophrenia, schizoaffective and schizophreniform disorders who received treatment with intramuscular (IM) administration of aripiprazole (ABILIFY (R)) ...

Otsuka and Lundbeck announced results from a Phase 3 clinical trial evaluating the efficacy, safety and tolerability of once-monthly aripiprazole intramuscular (IM) depot formulation for the ...

Oct. 13, 2004 (Stockholm) — The atypical antipsychotic aripiprazole (Abilify) is as effective as haloperidol and significantly more effective than placebo at treating acute agitation in psychotic ...

Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Lundbeck Pharmaceuticals LLC (Lundbeck) announce the US Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Abilify ...

ABILIFY MAINTENA (aripiprazole) 300mg and 400mg ext-rel injectable suspension Otsuka and Lundbeck announced results from the first-of-its-kind study comparing the effectiveness of aripiprazole ...

May 11, 2012 (Philadelphia, Pennsylvania) — Intramuscular depot aripiprazole is a safe and tolerable option for long-term maintenance treatment of schizophrenia, according to several presentations ...

Abilify (aripiprazole) is a prescription atypical antipsychotic that treats depression, schizophrenia, bipolar disorder, irritability related to autism, and specific Tourette's symptoms. While most ...

The Food and Drug Administration has approved the first digital pill for the US which tracks if patients have taken their medication. The pill called Abilify MyCite, is fitted with a tiny ingestible ...